Cancers,
Journal Year:
2020,
Volume and Issue:
12(6), P. 1475 - 1475
Published: June 5, 2020
Treatment
of
advanced
(metastatic)
non-small-cell
lung
cancer
(NSCLC)
is
currently
mainly
based
on
immunotherapy
with
antibodies
against
PD-1
or
PD-L1,
alone,
in
combination
chemotherapy.
In
locally
NSCLC
and
early
resected
stages,
also
employed.
Tumor
PD-L1
expression
by
immunohistochemistry
considered
the
standard
practice.
Response
rate
low,
median
progression
free
survival
very
short
vast
majority
studies
reported.
Herein,
numerous
biological
facets
are
described
involving
driver
genetic
lesions,
mutations
ad
fusions,
glycosylation,
ferroptosis
metabolic
rewiring
adenocarcinoma
(LUAD).
Novel
concepts,
such
as
immune-transmitters
effect
neurotransmitters
immune
evasion
tumor
growth,
nascent
relevance
necroptosis
pyroptosis,
possible
new
biomarkers,
gasdermin
D
E,
conundrum
K-Ras
LUADs,
growing
recognition
liver
kinase
B1
(LKB1)
pathways,
including
others,
commented.
The
review
serves
to
charter
diverse
treatment
solutions,
depending
main
altered
signaling
order
have
effectual
immunotherapy.
PDCD1
gene
(encoding
PD-1)
has
been
recently
described,
equilibrium
(encoded
PDCD1LG1).
Such
description
explains
hyper-progression,
which
reported
several
studies,
poises
fundamental
criterion
that
IHC
a
biomarker
should
be
revisited.
Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: March 22, 2024
Abstract
Inflammation
has
accompanied
human
beings
since
the
emergence
of
wounds
and
infections.
In
past
decades,
numerous
efforts
have
been
undertaken
to
explore
potential
role
inflammation
in
cancer,
from
tumor
development,
invasion,
metastasis
resistance
tumors
treatment.
Inflammation-targeted
agents
not
only
demonstrate
suppress
cancer
but
also
improve
efficacy
other
therapeutic
modalities.
this
review,
we
describe
highly
dynamic
complex
inflammatory
microenvironment,
with
discussion
on
key
mediators
including
cells,
cytokines,
their
downstream
intracellular
pathways.
addition,
especially
address
development
highlight
action
mechanisms
inflammation-targeted
therapies
antitumor
response.
Finally,
summarize
results
both
preclinical
clinical
studies
up
date
illustrate
translation
therapies.
International Journal of Molecular Sciences,
Journal Year:
2020,
Volume and Issue:
21(17), P. 6009 - 6009
Published: Aug. 20, 2020
IL-1
belongs
to
a
family
of
11
members
and
is
one
the
seven
receptor-agonists
with
pro-inflammatory
activity.
Beyond
its
biological
role
as
regulator
innate
immune
response,
involved
in
stress
chronic
inflammation,
therefore
it
responsible
for
several
pathological
conditions.
In
particular,
known
exert
critical
function
malignancies,
influencing
tumor
microenvironment
promoting
cancer
initiation
progression.
Thus,
orchestrates
immunosuppression
recruiting
pro-tumor
cells
myeloid
origin.
Furthermore,
new
recent
findings
showed
that
this
cytokine
can
be
directly
produced
by
positive
feedback
loop
contributes
failure
targeted
therapy.
Activation
anti-apoptotic
signaling
pathways
senescence
are
some
mechanisms
recently
proposed,
but
refractory
standard
therapies
needs
further
investigated.
Cell Death and Disease,
Journal Year:
2021,
Volume and Issue:
12(4)
Published: March 19, 2021
Hypopharyngeal
squamous
cell
carcinoma
(HPSCC)
is
one
of
the
most
common
malignant
tumors
in
otolaryngology
head
and
neck
surgery
worst
prognostic
tumors.
Endogenous
circular
RNA
(circRNA)
more
stable
than
mRNA,
microRNA
(miRNA),
long
non-coding
(LncRNA)
exosomes,
plasma,
urine,
participates
gene
expression
regulation
to
perform
different
functions.
Therefore,
circRNA
expected
become
a
biomarker
therapy
target
for
many
However,
function
regulated
by
N6-methyladenosine
(m6A)
are
still
unclear
HNSCC.
In
this
study,
we
demonstrated
that
specific
circRNA,
circCUX1,
was
upregulated
HPSCC
patients
who
resistant
radiotherapy
predicts
poor
survival
outcome.
We
further
found
methyltransferase
like
3
(METTL3)
mediated
m6A
methylation
circCUX1
stabilizes
its
expression.
Knockdown
promotes
sensitivity
hypopharyngeal
cancer
cells
radiotherapy.
addition,
binds
Caspase1
inhibits
expression,
resulting
decrease
release
inflammatory
factors,
thereby
developing
tolerance
Our
findings
indicate
potential
therapeutic
patients.
Cancers,
Journal Year:
2020,
Volume and Issue:
12(6), P. 1475 - 1475
Published: June 5, 2020
Treatment
of
advanced
(metastatic)
non-small-cell
lung
cancer
(NSCLC)
is
currently
mainly
based
on
immunotherapy
with
antibodies
against
PD-1
or
PD-L1,
alone,
in
combination
chemotherapy.
In
locally
NSCLC
and
early
resected
stages,
also
employed.
Tumor
PD-L1
expression
by
immunohistochemistry
considered
the
standard
practice.
Response
rate
low,
median
progression
free
survival
very
short
vast
majority
studies
reported.
Herein,
numerous
biological
facets
are
described
involving
driver
genetic
lesions,
mutations
ad
fusions,
glycosylation,
ferroptosis
metabolic
rewiring
adenocarcinoma
(LUAD).
Novel
concepts,
such
as
immune-transmitters
effect
neurotransmitters
immune
evasion
tumor
growth,
nascent
relevance
necroptosis
pyroptosis,
possible
new
biomarkers,
gasdermin
D
E,
conundrum
K-Ras
LUADs,
growing
recognition
liver
kinase
B1
(LKB1)
pathways,
including
others,
commented.
The
review
serves
to
charter
diverse
treatment
solutions,
depending
main
altered
signaling
order
have
effectual
immunotherapy.
PDCD1
gene
(encoding
PD-1)
has
been
recently
described,
equilibrium
(encoded
PDCD1LG1).
Such
description
explains
hyper-progression,
which
reported
several
studies,
poises
fundamental
criterion
that
IHC
a
biomarker
should
be
revisited.
